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Abstract
Background: Although analysis of microRNAs (miRNAs) by DNA microarrays is gaining in popularity, these new 
technologies have not been adequately validated. We examined within and between platform reproducibility of four 
miRNA array technologies alongside TaqMan PCR arrays.
Results: Two distinct pools of reference materials were selected in order to maximize differences in miRNA content. 
Filtering for miRNA that yielded signal above background revealed 54 miRNA probes (matched by sequence) across all 
platforms. Using this probeset as well as all probes that were present on an individual platform, within-platform 
analyses revealed Spearman correlations of >0.9 for most platforms. Comparing between platforms, rank analysis of the 
log ratios of the two reference pools also revealed high correlation (range 0.663-0.949). Spearman rank correlation and 
concordance correlation coefficients for miRNA arrays against TaqMan qRT-PCR arrays were similar for all of the 
technologies. Platform performances were similar to those of previous cross-platform exercises on mRNA and miRNA 
microarray technologies.
Conclusions: These data indicate that miRNA microarray platforms generated highly reproducible data and can be 
recommended for the study of changes in miRNA expression.
Background
DNA microarray technologies are powerful tools that can
be used to quantify differences in the amount of specific
DNA or RNA sequences between samples. Recently,
application of this technology has extended to the mea-
surement of changes in the abundance of microRNAs
(miRNA). MiRNAs are a class of small non-coding RNAs
(typically 21-25 nucleotides in length) that bind to
mRNAs to regulate protein expression either by blocking
translation or by promoting degradation of the mRNA
transcript [1]. These molecules are implicated in a large
number of biological processes and human diseases (e.g.,
[2-8]). As such, hundreds of papers in the past five years
have been published using microarray technologies to
explore changes in miRNA abundance.
Despite its widespread application, only three papers
have systematically investigated the reproducibility of
results produced between different miRNA detection
technologies [9-11], with only one specifically comparing
microarray platforms [11]. Early studies examining the
reproducibility and correlation among microarray tech-
nologies for the detection of mRNA gene expression
revealed very poor correlations, in part related to sub-
optimal protocols, incomplete or incorrect annotation of
early platforms, incorrect probe-matching between tech-
nologies, differences in data normalization, inadequate
pre-filtering of probes that had low signal intensities, and
lab-lab variation in technical abilities (reviewed in [12]).
Later large-scale studies on more accurately annotated
platforms applied appropriate probe-matching tech-
niques, mathematical modeling and filtering techniques
to reveal a very high correlation among mRNA microar-
ray detection technologies both within and across labora-
tories (e.g., [13-16]). It is expected that the lessons
learned from these early mRNA platforms will result in
fewer problems associated with reproducibility among
novel array-based nucleic acid technologies in the future.
Nevertheless, as miRNA technologies are new and signif-
icant differences exist in the probe design and experi-
mental protocols associated with the various
commercially-available platforms, it is essential to inves-
tigate the correlation and reproducibility among these
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variability are associated with miRNA profiling and it has
been suggested that much more work is required to iden-
tify and minimize these technical variables and increase
reliability and credibility of miRNA profiles (reviewed in
[17]).
In the present study we investigate intra- and inter-plat-
form correlation among 4 miRNA microarray technolo-
gies (Agilent Technologies, Exiqon, Invitrogen, LC
Sciences) using commercially-available reference materi-
als. We also investigate the rank correlation of miRNA
expression on microarray platforms and miRNA expres-
sion using TaqMan qPCR-arrays.
Results
We created two reference samples using commercially-
available mouse reference RNA. The two references were
selected to ensure differences in miRNA abundance
between the samples (i.e., to optimize the number of dif-
ferentially expressed miRNA), similar to the methods
described by Irizarry et al. [18]. Reference 1 was created
by pooling RNA derived from mouse testicle, ovary and
from embryos, while liver, heart and lung were pooled to
create Reference 2. Aliquots from these four references
were hybridized to four genome-wide microarray tech-
nologies (Agilent, Exiqon, Invitrogen NCode and LC Sci-
ences). The results from these arrays were compared to
each other, and were then compared to the TaqMan
miRNA PCR arrays produced from the same samples.
The Agilent and LC Sciences arrays were carried out in 1
color, with 2 replicates per Reference pool. The Exiqon
and Invitrogen NCode arrays were analyzed in two col-
ors. For the two-color arrays, Reference 1 was labelled
with Cy3 (Exiqon) or Alexa Fluor 3 (Invitrogen NCode),
with Reference 2 labelled with Cy5 or Alexa Fluor 5, and
then a dye swap was carried out. This was done twice for
a total of 4 microarrays per platform. All microarray anal-
yses presented herein were based on a sample size of 4
(two replicates of Reference 1 and two replicates of Refer-
ence 2 for each platform). To ensure that the different
platforms were maximally comparable, each of the two-
color platforms were also analysed in one-color format.
The Exiqon platform was thus analysed for the Cy3 chan-
nel only, with the NCode platform analysed for the Alexa
Fluor 5 channel only. In general, inter-platform correla-
tions were highest for both platforms when data were
analyzed in two-colors, though this reduced intra-plat-
form reliability specifically for the NCode platform.
One process that can introduce discrepancies between
the results produced by different platforms is the selec-
tion of the appropriate normalization algorithm. Various
methods have been proposed for miRNA arrays. In the
present study, microarray data from each of the technolo-
gies were normalized using a cyclic lowess approach for
1-color analyses, and a dye swap with lowess normaliza-
tion for 2-colors. Initial analysis revealed that the plat-
form correlations were slightly higher using this approach
than using a quantile normalization (data not shown).
Cyclic lowess normalization assumes an equal proportion
of up-regulated and down-regulated probes, and this
assumption was not violated in the current dataset (data
not shown).
MiRNA sequences are extremely short, and thus the
problems associated with probe matching that compli-
cated the comparison of gene expression profiles across
technologies are less relevant. However, the various plat-
forms' probes were developed using different miRBase
databases and thus should not be matched by name alone.
Thus, to compare across platforms probes were matched
by sequence. Technical replicates of probes were spotted
on all of the array technologies; the medians of these
technical replicates were used for the subsequent analy-
ses. Using this approach there were 189 probes in com-
mon across the 4 microarray technologies. Among these
probes, 54 yielded signal intensities that were signifi-
cantly above background (i.e., 'present') on all platforms
and were also included on the TaqMan arrays. Venn dia-
grams for present probes are found in Additional Files 1
and 2 (File 1: Figure S1; File 2: Figure S2). In general the
detection of probes between pairwise comparisons was
quite similar, with no single platform greatly influencing
the overall number of probes in common. When compar-
ing both within and between platforms, correlation anal-
yses were performed on two different probe sets. First, to
ensure calculations were based on maximum numbers of
miRNAs, correlations were determined for all miRNAs
that were 'present' on both platforms being compared.
Second, in order to ensure a fair comparison across all
platforms, correlation analyses were performed on the
subset of 54 miRNAs present on all platforms.
We examined within-platform quality metrics and
reproducibility to get a general sense of the performance
of each platform. The numbers of miRNAs detected
within the platforms were very similar (122 miRNAs
present for Agilent, 131 for Exiqon, 118 for Invitrogen
NCode, and 131 for LC Sciences). A rank correlation
analysis was carried out to evaluate the precision of the
platforms (i.e., correlation of technical replicates). Spear-
man correlation analysis revealed a very high level of
reproducibility within platforms for all four of the
miRNA microarray platforms (Table 1). The poorest
reproducibility was observed for the Invitrogen NCode
platform, particularly when two-color data were ana-
lyzed. Closer inspection revealed that signal quality was
relatively low for the Alexa Fluor 3 channel which led to
greater differences in comparisons between the dyes.
Exclusion of data from this channel through single-color
data analysis greatly improved reproducibility to 0.850.
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Probe Technology MiRBase 
version
One or two-
color analysis
Number of 
miRNAs 
considered
Correlation Standard Error 95% 
Confidence 
intervals
Agilent Mouse 
miRNA (P/
NG4472A)
60 mer probes with hairpin 
loop structure and 5'G residue 
complement to the C residue 
added to the microRNA 
during labelling
MirBase 12 One 122 0.995 0.0014 0.991-0.997
54 0.995 0.0035 0.984-0.997
LC Science 
Mouse miRNA 
Microarray 
MRA-1002
μParafloTM Technology uses 
proprietary in-situ oligo 
synthesis, microfluidic 
reaction cells, and novel 
photochemistry coupled with 
photolithography; full 
content flexibility
MirBase 12 One 131 0.978 0.0068 0.961-0.987
54 0.981 0.0105 0.952-0.992
Exiqon 
miRCURY LNA™ 
microRNA 
Array kit
LNA Locked Nucleic Acids are 
conformationally locked into 
a favourable confirmation for 
miRNA binding
MirBase 11 Two 131 0.914 0.0189 0.870-0.944
54 0.913 0.0258 0.848-0.948
One 125 0.874 0.0330 0.798-0.925
54 0.802 0.0723 0.631-0.910
Invitrogen 
NCode Multi-
Species miRNA 
Microarray 
Probe Set V2
34-44 nucleotide probes 
designed as dimers of 
sequences complementary to 
mature miRNAs, trimmed to 
reduce melt temperature 
variability between probes.
MirBase 9 Two 118 0.706 0.0544 0.586-0.798
54 0.816 0.0532 0.686-0.892
One 124 0.853 0.0338 0.775-0.907
54 0.850 0.0553 0.716-0.928
Spearman correlations and the 95% confidence intervals are presented for the miRNAs that were present within a platform from the sequence-
matched list, as well as the 54 miRNAs that gave detectable signals on all four platforms.
Reliability of this platform may have also been compro-
mised by printing arrays in-house, and indeed, correla-
tions of the other commercial platforms were higher
(0.913-0.995). We note that a very high level of within-
platform correlation was obtained for LC Sciences,
despite using sub-optimal hybridization conditions
(starting total RNA was limiting).
A rank correlation analysis was applied to compare
across the technologies, where the two reference samples
were used to derive log ratios (i.e., relative expression).
Log ratios were generated using all combinations of refer-
ences pairs. A Spearman correlation was then used to
examine the relationship across technologies (Table 2; see
Additional file 3: Table S1 for complete dataset). For the
two-color platforms, these comparisons were based on
both one- and two-color analyses, each of which are pre-
sented in Table 2. However, discussion of the data com-
paring Exiqon and Invitrogen NCode platforms to other
arrays will be restricted to the two-color analyses, given
that these platforms were designed as two-color plat-
forms and were run in two color form, and therefore
there is potential for cross-talk or competitive hybridiza-
tion between the channels. A high level of correlation was
observed between all array platforms. Correlation coeffi-
cients ranged from 0.765-0.949 in analyses based on miR-
NAs present on the two platforms being compared, or
0.731-0.949 based on the 54 miRNAs present across all
platforms. Analysis of the 54 miRNAs in common
revealed a higher correlation coefficient for Agilent vs
Exiqon compared to the other platform contrasts. How-
ever, there was a high degree of overlap of the confidence
intervals across the correlation analyses. Scatterplots
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Additional file 4). Although the present probes revealed
higher R2 values (range 0.431-0.867), probes within the
background were also positively linearly associated (R2
range 0.214-0.741).
Because qRT-PCR is used to validate the results of
microarray experiments, we used TaqMan miRNA arrays
to explore the correlation of arrays with qRT-PCR. This
analysis is aimed at evaluating the potential accuracy of
the microarrays, as described in [18]. The differences on
the log2 scale were multiplied by -1 in order to derive a
positive correlation coefficient, since low Ct values are
associated with high expression (i.e., the opposite of DNA
microarrays). All miRNAs that were present on the
miRNA arrays yielded Ct values equal to, or less than 25.
Thus, these miRNAs exhibited Cts that were well within
the range of detection of this method [19]. Spearman cor-
relation analysis revealed a high level of agreement
between the TaqMan and miRNA arrays (Table 3). The
average correlation coefficients were 0.68 (miRNA pres-
ent in a pairwise contrast) and 0.65 (using the 54 miRNAs
present across all platforms). Irrespective of the analysis
employed (one- or two-color, or miRNAs present in each
pair-wise contrast, or all miRNAs present in all plat-
forms), correlations ranged from 0.642-0.775. The only
exception was in correlations between LC science arrays
and RT-PCR using the restricted set of 54 miRNAs,
which gave a correlation of 0.51. This correlation was sig-
nificantly lower than those observed with some of the
other platforms, though significance was marginal and is
lost after family-wise error rate correction (Additional
File 5: Table S2). Concordance correlation coefficients
(CCCs) were calculated for the 54 miRNAs in common
and present, as well as for the miRNAs that were present
on an individual microarray platform. These data are
summarized in Table 4. In contrast to the rank correla-
tion analysis, LC Sciences exhibited the highest CCC in
this analysis, with NCode 2 colour demonstrating the
lowest. However, analysis of the 54 miRNA in common
among all platforms revealed a high overlap among the
95% confidence intervals, and thus did not reveal any sig-
nificant differences between the platforms.
Discussion
New technologies for the analysis of changes in miRNA
expression are widely used but have not been adequately
validated. We examined within and between platform
correlation of four DNA array technologies for miRNA
analysis as well as TaqMan PCR arrays. Within-platform
correlations provide an estimate of the array reproduc-
ibility, while comparison to RT-PCR provides insight into
the accuracy of the platforms as described in Irizarry et
al. [18]. Two distinct pools of commercially-available ref-
erence materials were selected in order to maximize dif-
ferences in miRNA content. All analyses were based on
the log ratios of these two distinct samples as recom-
mended in prior cross-platform microarray publications
[14,18,20,21]. Aliquots from the same reference samples
were used for all technologies to ensure comparability.
Because LC Sciences was the last technology that we
explored, miRNA concentration was limiting for this
platform. As such, the protocol used was not according to
the supplier's recommendation. Thus, we expect the
results of this platform would improve if more total RNA
was used. Probes across microarray technologies were
matched by sequence to avoid errors in annotation result-
ing from the development of probes from different ver-
sions of miRBase. Filters were applied to remove miRNAs
that gave signal intensities within the background, and
the same normalization protocol was applied across the
technologies. All analyses were carried out on a subset of
genes that passed all these quality metrics. Moreover, two
color platforms were also examined using a one-color
approach to minimize differences across technologies.
Using this stringent data handling protocol we calcu-
lated the within-platform variability to determine the
precision of the platforms [18]. This analysis revealed a
high level of reproducibility within a given technology
(Table 1). The Invitrogen NCode array exhibited the low-
est within-platform correlation. This may be expected as
these arrays were printed in-house, and both quality and
reproducibility of a commercial product should be much
higher. Moreover, we obtained poor signal quality on one
of the channels, and a one-color analysis of this platform
greatly improved reliability. Indeed, with the exception of
the two-color NCode analysis, within-platform analyses
revealed very high Spearman correlation for all pairwise
contrasts, ranging from 0.850-0.995. These within plat-
form correlation coefficients are within the same range as
those of previous cross-platform and cross-institute exer-
cises on mRNA microarray platforms (e.g., [18,21]) and
microRNA technologies [11]. For example, Sato et al.
obtained correlation coefficients for miRNA arrays that
ranged from 0.83 to 0.99, depending on the tissue origin
of the miRNA samples [11]. These data indicate that the
four microarray platforms generated highly reproducible
data that are in-line with previous cross-platform papers.
Further analyses also revealed a high level of reproduc-
ibility across technologies. Spearman correlation coeffi-
cients were generated for each possible pairwise contrast
for each of the microarray technologies using miRNAs
that were present across all platforms (n = 54) or in com-
mon between specific pairwise contrasts (Table 1). Scat-
terplots were produced for both present and absent
miRNAs (Additional file 4). Spearman analysis compares
the log ratio ranks (Reference 1 to Reference 2) to deter-
mine whether the distribution of fold changes is similar.
Focusing on the two-color analyses for Invitrogen NCode
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designed and hybridized), the average cross-platform
correlation coefficient for all platform comparisons was
0.82 (range of 0.731-0.949) using the 54 miRNAs present
across all platforms, with a large amount of overlap in the
confidence intervals. Scatterplots for all pair-wise com-
parisons (Additional file 4) yielded very similar findings.
The cross-platform correlations are consistent with pre-
vious work on mRNA expression arrays [14,16] and with
the single previous study examining miRNA array plat-
forms [11]. For example, Spearman rank correlation coef-
ficients for cross-platform analyses ranged from 0.590 to
0.941 in the MAQC consortium [21]. Rank correlation
analysis of miRNA arrays revealed a median rank correla-
tion of 0.55 (using only detectable miRNAs); the highest
correlation found was 0.87 [11]. Thus, the results of the
present study reveal correlation coefficients that overlap
with the high end of these previous cross-platform analy-
ses. As such, we conclude that results generated by these
different technologies are highly concordant.
The highest correlation was found between Agilent and
Exiqon (Table 2). Results for this comparison were signif-
icantly higher than most of the other comparisons. We
routinely use the Agilent platform for all of our gene
expression studies, and thus expected within-and
between-platform correlations for Agilent to be high.
Moreover, the Agilent and Exiqon platforms were the
first experiments to be run, and were run inside our labo-
ratory, while LC Sciences and NCode were done in other
laboratories (see Methods). As LC Sciences was the last
platform analyzed, the amount of RNA available was well
below the company's recommended protocol. Thus, we
caution that the finding that one platform is better than
the others, or that Exiqon and Agilent produce more cor-
Table 2: Between platform pairwise correlations for miRNA arrays.
Agilent LC Sciences Exiqon 2 Exiqon 1 NCode 2 NCode 1
Agilent 0.794 0.676-0.870 (71) 0.949 0.905-0.970 (72) 0.892 0.811-0.940 (69) 0.770 0.628-0.863 (70) 0.768 0.623-0.865 (72)
LC Sciences 0.757 0.617-0.849 (54) 0.824 0.730-0.882 (72) 0.766 0.646-0.843 (70) 0.765 0.649-0.843 (71) 0.663 0.491-0.790 (75)
Exiqon 2 0.949 0.892-0.974 (54) 0.794 0.664-0.876 (54) 0.943 0.895-0.967 (81) 0.808 0.680-0.890 (71) 0.750 0.604-0.849 (74)
Exiqon 1 0.867 0.756-0.931 (54) 0.722 0.559-0.832 (54) 0.927 0.849-0.966 (54) 0.823 0.702-0.897 (68) 0.771 0.631-0.864 (71)
NCode 2 0.843 0.715-0.918 (54) 0.731 0.562-0.843 (54) 0.869 0.751-0.934 (54) 0.884 0.778-0.943 (54) 0.891 0.800-0.943 (76)
NCode 1 0.822 0.664-0.917 (54) 0.672 0.446-0.830 (54) 0.814 0.664-0.905 (54) 0.822 0.676-0.909 (54) 0.935 0.865-0.966 (54)
Spearman correlations and the 95% confidence intervals are presented for miRNA present in individual pairwise-contrasts (above diagonal) or using the 54 
sequence-matched miRNAs with detectable signals on all four miRNA platforms. Numbers in brackets indicate the number of miRNA probes used in deriving 
the analysis.
Table 3: MiRNA array correlations with TaqMan arrays.
One or two-color 
analysis
Number of 
miRNAs 
considered
Correlation Standard Error 95% Confidence 
intervals
Agilent One 122 0.692 0.0633 0.553-0.799
54 0.653 0.1073 0.414-0.831
LC Science One 131 0.680 0.0590 0.548-0.782
54 0.506 0.1215 0.241-0.762
Exiqon Two 131 0.700 0.0569 0.575-0.799
54 0.656 0.1079 0.412-0.835
One 125 0.700 0.0598 0.567-0.804
54 0.691 0.1009 0.467-0.855
Invitrogen NCode Two 118 0.642 0.0567 0.517-0.737
54 0.775 0.0850 0.575-0.907
One 124 0.659 0.0573 0.533-0.759
54 0.730 0.0896 0.521-0.873
Spearman correlations and the 95% confidence intervals are presented for all the miRNAs that were present on a platform, or using the 54 
sequence-matched miRNAs that were detected by all four microarray technologies.
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experiment. Indeed, our primary interpretation of the
data is that the platforms show a high level of similarity to
each other despite being hybridized in different labs, at
different times, with different protocols and amounts of
expertise.
We examined the correlation of the log ratios between
the array platforms and miRNA expression measured
using TaqMan arrays, as qRT-PCR is often considered to
be the 'gold standard' for validation. All miRNA that were
'present' on the array technologies yielded Ct values that
were equal to, or less than, 25. The correlation coeffi-
cients from this analysis ranged from 0.506-0.775. This is
much higher than a previous publication examining the
correlation between TaqMan PCR arrays and miRNA
arrays, which yielded a correlation coefficient of 0.44,
suggesting considerable variability between the
approaches [10]. However, these numbers are in-line with
the previous study on miRNA arrays that compared sev-
eral platforms to TaqMan arrays, and found a range of
correlation coefficients from 0.44 to 0.86 (including 0.85
for Agilent and 0.67 for Exiqon) [11]. This analysis is
aimed at estimating the potential accuracies of the plat-
forms. Using the 54 miRNAs that were present among all
platforms, LC Sciences exhibited the lowest rank correla-
tion coefficient with TaqMan, however, this may be due
to small sample size. Indeed, the correlation coefficient
for the 122 miRNAs present on that platform was 0.680,
in-line with the other platforms. Moreover, analysis of
CCCs for this platform (against TaqMan arrays) revealed
the highest coefficients. CCC incorporates measures of
both accuracy and precision in one index and is proposed
to be a universal measure of study quality [22,23]. The
precision is not based on ranks, and thus will give slightly
different result than the above Spearman rank correlation
analysis. The ranges of CCCs were in-line with data pro-
duced for Affymetrix gene expression data against RT-
PCR [23]. In the present analysis, LC Sciences exhibited
the highest CCC, however, comparisons among the 54
sequence-matched miRNAs that were present on all plat-
forms revealed overlap among the confidence intervals
(i.e., no significant differences among the platforms).
These combined data indicate that there were minimal
differences in correlation with TaqMan among the tech-
nologies, and all platforms perform well relative to
mRNA expression arrays.
The present study is complementary to a recent elegant
paper by Sah et al. [24], which employed a very different
experimental design to evaluate performance of multiple
miRNA microarray platforms. In our study, we compare
different biological samples to evaluate reliability of
arrays within and between platforms, as well as between
technologies (i.e., microarray vs. RT-PCR). In contrast,
Sah et al., used dilution series of spike-in positive controls
on four microarray platforms to evaluate the platforms.
Specifically, they determined accuracy/sensitivity
(defined as whether arrays revealed expected changes in
signal intensity following known changes in spike-in con-
centration, over a wide range of concentrations) and
specificity/precision (changes in signal intensity specific
only to probes for the manipulated spike-in controls, or
changes observed for other miRNAs for which signal
intensity is expected to be unaltered). As with our study,
while differences were detected between the platforms,
all four arrays performed well in each measure of array
quality.
Table 4: Correlation between miRNA arrays and TaqMan arrays.
One or two-color analysis Number of miRNAs considered CCC 95% Confidence intervals
Agilent One 122 0.416 0.337-0.488
54 0.405 0.268-0.527
LC Science One 131 0.545 0.454-0.624
54 0.610 0.451-0.732
Exiqon Two 131 0.461 0.371-0.542
54 0.532 0.377-0.657
One 125 0.409 0.329-0.483
54 0.459 0.320-0.579
Invitrogen NCode Two 118 0.314 0.241-0.383
54 0.435 0.315-0.540
One 124 0.225 0.225-0.281
54 0.344 0.243-437
Concordance correlation coefficients and the 95% confidence intervals are presented for all the miRNAs that were present on a platform, or 
using the 54 sequence-matched miRNAs that were detected by all four microarray technologies.
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We conclude that the knowledge acquired from early
work on the technical issues related the protocols and
data processing methods applied to gene expression
microarrays have greatly facilitated the rapid implemen-
tation of highly-reproducible data using miRNA arrays.
The four platforms examined in the present study show
high levels of both within- and between-platform repro-
ducibility. The platforms also correlate well with TaqMan
arrays. We would recommend any of the methodologies
listed in this paper for the study of changes in miRNA
expression.
Methods
Reference miRNA materials
Reference RNA was developed from FirstChoice® mouse
Total RNA including the small fraction (Catalogue #
AM7800-AM7828, Ambion, Streetsville, ON). Two refer-
ences were made from the various stocks. Reference # 1
was a pool of equal amounts of total RNA from mouse
testicle, ovary and 10-12 day embryo. Reference #2 was a
pool of equal parts total RNA from mouse liver, heart and
lung. Aliquots from the reference RNA pools were ana-
lyzed in the following order: Agilent (in-house), Exiqon
(in-house), NCode (outsourced to Carleton University),
TaqMan PCR arrays (out-sourced to the University of
Montreal, Montreal, Quebec), followed by LC Sciences
(outsourced to LC Sciences in Houston, Texas) over the
period of June-September in 2009.
miRNA expression profiling using Agilent arrays
Agilent miRNA arrays were performed in one color at
Health Canada, Ottawa, with all samples on a single
8_x_15k microarray, according to the manufacturer's
instructions (Agilent Technologies). Briefly, 100 ng refer-
ence RNA was dephosphorylated by incubation with calf
intestinal phosphatase at 37°C for 30 min and denatured
using 100% DMSO at 100°C for 5 min. Samples were
labelled with pCp-Cy3 using T4 ligase by incubation at
16°C for 1 hour. Each labelled RNA sample was hybri-
dised to an individual array on 8_x_15K format Agilent
mouse miRNA array slides, with each array containing
probes for 567 mouse miRNAs and 10 mouse gamma
herpes virus miRNAs. Four arrays were hybridised with
Reference #1, and four arrays were hybridized with Refer-
ence #2. Hybridisations were performed in SureHyb
chambers (Agilent) for 20 hours at 55°C. Arrays were
washed according to manufacturer's instructions and
scanned at a resolution of 5 μm using an Agilent G2505B
scanner. Data were acquired using Agilent Feature
Extraction software version 9.5.3.1. One array yielded a
very poor hybridization signal and did not pass the Agi-
lent quality control metrics in the Feature Extraction soft-
ware. Two arrays from each Reference sample were
randomly chosen for the subsequent analyses.
miRNA expression profiling using Exiqon arrays
Exiqon arrays were performed in two colors at Health
Canada, Ottawa, according to manufacturer instructions.
One microgram of each mouse Reference RNA sample
was labelled with a Hy5 fluorophore (Exiqon, Woburn,
MA, USA) and co-hybridised with 1 μg of the other Ref-
erence RNA standard in Hy3. Two replicates were per-
formed as well as two dye swaps (i.e., a total of 4 arrays
hybridized). Labelling reactions were performed using
Exiqon's miRCURY LNA miRNA power labelling kit,
according to the manufacturer's protocol. Briefly, 5' phos-
phates were removed using calf intestinal phosphatase.
Hy3 or Hy5 fluorescent molecules were attached enzy-
matically to the 3' end of the miRNAs. Hy3 and Hy5
labelled samples were co-hybridised to Exiqon multi-spe-
cies miRCURY LNA miRNA array slides (version 11.0),
containing ~1700 capture probes covering all human,
mouse and rat miRNAs annotated in miRBase 11.0.
Hybridisations were performed in SureHyb chambers
(Agilent) for 16 hours at 56°C. Slides were washed
according to manufacturer's instructions and scanned at
5 μm resolution using an Agilent G2505B scanner. Data
were acquired using Agilent Feature Extraction software
version 9.5.3.1, using an FE protocol available on-demand
from Exiqon.
miRNA expression profiling using Invitrogen NCode arrays
NCode arrays (Invitrogen) were performed in two colors
at Carleton University, Ottawa, according to manufac-
turer instructions. Custom arrays were printed in house
using the Invitrogen NCode Multi-Species miRNA
Microarray Probe Set V2 (Invitrogen) which includes
1140 probes covering six different species, including 427
mouse miRNA probes designed from the Sanger miR-
Base Sequence Database, Release 9.0. The probe set was
modified to incorporate dilution series for endogenous
miRNAs and spike-in controls, print-tip carry-over con-
trols, and random hexamer negative controls based on
the design described by Yauk et al [25]. Following Invitro-
gen guidelines, probes were dissolved at 30 μM in
Pronto!™ Epoxide Slide Spotting Solution (Corning) and
printed on Epoxide-Coated Slides (Corning) using the
VersArray ChipWriter Pro (BioRad), with each spot repli-
cated 6 times per array. Arrays were pre-soaked and pre-
hybridized according to manufacturer's instructions
(Corning). Two replicates and two dye-swaps (i.e., 4
arrays) were performed. For each labelling reaction, 0.5
μg of total reference RNA was spiked with 40 fmoles
NCode Microarray Positive Control (Invitrogen) and
labelled using the NCode Rapid miRNA Labelling System
according to manufacturer's instruction (Invitrogen).
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Page 8 of 10Briefly, polyA polymerase is used to add a poly(A) tail to
the RNA, to which is then ligated a DNA polymer carry-
ing ~15 molecules of the fluorophore (Alexa Fluor® 3 or
5). Ligation is mediated by an oligo(dT) bridge whose
sequence matches both the poly(A) tail of the RNA, and
the fluorophore-labelled DNA polymer. Arrays were
hybridized 10 hours at 52°C. In a modification of the
standard protocol, hybridizations were performed using
Agilent hybridization chambers within a rotisserie oven,
which required dilution of the hybridization mix to a total
volume of 120 μl, by addition of BSA (8 mg/ml) and
Enhanced Hybridization Buffer (Invitrogen). Arrays were
washed and dried by centrifugation according to manu-
facturer's instructions. To protect dyes against ozone-
mediated degradation, 0.1 mM dithiothreitol was added
to each wash solution, and slides were dried and stored in
sealed tubes containing 20 μl of ≥ 98% 2-mercaptoetha-
nol, ensuring that there was no contact between the
reducing agent and the array. Arrays were scanned with a
GenePix 4000B laser scanner (Molecular Devices) with a
scan resolution of 5 μm, and PTM between 620 to 660 V.
Non-background-subtracted signal intensity was deter-
mined using Imagene 8.0 image analysis software (Biodis-
covery, Inc.).
miRNA expression profiling using LC Sciences
LC Sciences arrays were performed in one color by the
company at the LC Sciences Headquarters (Houston, TX)
using two replicates of each reference pool. This platform
contains all known mouse miRNA from the Sanger miR-
Base database (release 14.0). The assay used lower start-
ing quantities of total RNA because RNA was limiting
(recommended 5-8 μg). Thus, the protocol was sub-opti-
mal for this platform. Briefly, 1 μg of total reference RNA
was extracted with Trizol reagent (Invitrogen) and size
fractionated using a YM-100 Microcon filter (Millipore).
Small RNAs less than 300 nucleotides in length were
extended with a poly(A) tail using poly(A) polymerase.
Poly(A) tails were ligated with an oligonucleotide tag for
subsequent dye staining. Hybridizations were carried out
overnight on μParaflo microfluidic chip using a micro-
circulation pump (Atactic Technologies) [26,27] using
100 μL 6× SSPE buffer (0.90 M NaCl, 60 mM Na2HPO4, 6
mM EDTA, pH 6.8) containing 25% formamide at 34°C
overnight. Each detection probe on the microfluidic chip
consisted of a chemically-modified nucleotide coding
segment complementary to target microRNA or other
RNA (control sequences), and a spacer segment of poly-
ethylene glycol to extend the coding segment away from
the substrate. The detection probes were made by in situ
synthesis using PGR (photogenerated reagent) chemistry.
After RNA hybridization, tag-conjugating Cy3 dyes were
circulated through the microfluidic chip for dye staining.
Images were acquired using a GenePix 4000B (Molecular
Device) laser scanner. Intensity data were collected using
Array-Pro image analysis software (Media Cybernetics)
with a scan resolution of 10 microns and PTM between
480 and 540 V. Analysis was conducted on background
subtracted signal intensities. Background was determined
using a regression-based background mapping method.
Spots yielding true signal (i.e., present) had signal intensi-
ties higher than 3 ×(background standard deviation) and
standard deviation/signal intensity < 0.5. CV is calculated
by (standard deviation)/(signal intensity). Probes
repeated multiple times on an array were called present if
the signals from at least 50% of the probes were above
detection level.
Normalization and data processing
For two-color analyses, a dye swap was applied followed
by a lowess normalization. For analysis in one color on
Agilent, Exiqon and Invitrogen NCode arrays, non-back-
ground subtracted median signal intensities were cyclic-
lowess normalized [28] in R [29]. Cyclic lowess normal-
ization is a one colour normalization method which is a
modification of lowess normalization for two colour
studies. The method estimates a lowess curve for all dis-
tinct pairwise combinations. For all pairs of arrays for any
array k where 1 = k = n, the adjustments for array k rela-
tive to the other arrays are averaged and applied to the
raw data to obtain the normalized data [28]. The Cy3
channel was used for the Exiqon slides because Cy3 was
used for LC Sciences and Agilent. The Alexa Fluor 5
channel was used for the NCode arrays because the Alexa
Fluor 3 channel produced lower quality of data. The
background for the Agilent array was measured using the
(-)3xSLv1 probe, using the hsa_negative_control_1
probes for the Exiqon platform, and using the pool of
random hexamers for NCode arrays. Spots with median
signal intensities less than the trimmed mean plus three
trimmed standard deviations of these negative controls
were flagged as absent. A trimmed mean or truncated
mean is a statistical measure of central tendency, where a
percent of the high and low ends of a distribution are
removed and the mean is calculated using the remaining
data of the remaining distribution. In the present study
the trim (or proportion of data removed) was set at 5%.
MiRNA technical replicates were then averaged by taking
the median of the technical replicates. The collapsed
observation was flagged as absent if at least one of the
values used to calculate the average was flagged.
Data processing of LC Sciences arrays was carried out
by LC Sciences using their standard data analysis meth-
ods. Briefly, cyclic-lowess (locally-weighted regression)
normalization was carried out on background-subtracted
data according using the same methods as those
described above and in [28]. Transcripts were considered
to be present if the signal intensity was greater than 3 ×
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Page 9 of 10(background standard deviation) and the spot CV < 0.5
(where CV = (standard deviation)/(signal intensity)).
Normalized and raw intensity values for all microarray
data have been deposited in the NCBI Gene Expression
Omnibus database under the accession number
GSE19669.
TaqMan arrays
Reference pools 1 and 2 were analyzed using TaqMan®
rodent microRNA arrays v2.0 (A and B) (Applied Biosys-
tems). These arrays represent 585 mature miRNA derived
from Sanger miRBase v10 analyzed over two 384-well
PCR plates. RT-PCR reactions were carried out using the
manufacturer's recommendation. In brief, 1 μg of total
RNA was reverse transcribed using Megaplext RT Prim-
ers and TaqMan miRNA reverse transcription kids.
Quantitative RT-PCR was performed at the University of
Montreal http://www.iric.umontreal.ca/Recherche/
Plates_Formes/Genomique_EN.html using an Applied
Biosystems 7900HR system and TaqMan universal PCR
master mix using the following conditions: 10 min at
94.5°C followed by 40 cycles of 97°C for 30 s and 59.7°C
for 1 min. Cycle threshold (Ct) values were calculated
using the SDS2.2.2 using the automatic baseline and
threshold of 0.2. Normalized expression (NE) was calcu-
lated using NE = 2expDeltaDeltaCt, where Ct is the
threshold cycle to detect fluorescence. The data were
normalized to miRNA U6. Ct values that were greater
than 35 were considered to be below the detection
threshold of the assay [19].
Filtering and statistical analysis
Because miRNA probes from the various platforms were
based on different MiRBase databases (Table 1), probes
were first mapped by sequence. This was a straightfor-
ward process relative to matching mRNA probes, as
miRNA are very short. All the data were first merged
using the name of the miRNA. Sequence matching was
then carried out. The Agilent probe sequences were
shorter than the probes from the other platforms. If the
Agilent probe sequence was contained within a probe
from the other platforms, it was considered a match.
Spearman correlations were determined for within-
platform comparisons and for between-platform compar-
isons. Correlations were calculated separately for the set
of miRNAs that were either 1) detectably expressed as
'present' on the two arrays being compared, or 2) detect-
ably expressed on all four array platforms and gave mea-
surable Ct values using RT-PCR.
Within platform correlations were conducted either
using all miRNAs detectably expressed as present on that
platform, or using the miRNAs that were present on all
four platforms and gave measurable Ct values using RT-
PCR. The Spearman correlation between log2(Ref. 1A/
Ref. 2A) vs. log2(Ref. 1B/Ref. 2B) and log2(Ref. 1A/Ref. 2B)
vs. log2(Ref. 1B/Ref. 2A) were averaged, and standard error
and 95% confidence intervals were obtained using the
bootstrap [30].
Spearman correlations between the mean relative dif-
ferences (log2) for each platform to the relative difference
obtained from RT-PCR were estimated. Standard Errors
and 95% confidence intervals were obtained as above.
Similarly, for comparisons between different array plat-
forms, Spearman correlations with standard errors and
95% confidence intervals for mean relative differences
(log2) were also estimated. Similar to the within-platform
correlations, all correlations were determined based on
either all miRNAs that were detectably expressed on the
two platforms being compared, or all miRNAs that were
detectably expressed on all four array platforms, plus the
RT-PCR arrays. The Concordance correlation coefficient
[23] (CCC) analysis was conducted using the epiR R
library 2 [31].
Finally, two of the platforms evaluated were one-color
arrays (Agilent, LC Science) with two platforms running
two-color arrays (Exiqon, Invitrogen NCode). To evaluate
whether this distinction led to increased differences
between platforms, each of the two-color arrays were
analyzed both as a two-color arrays, and as a one-color
array.
List of Abbreviations
miRNA: microRNA
Additional material
Additional file 1 Number of miRNAs in common (from Present miR-
NAs only; 2-color data). A Venn diagram depicting the overlap of miRNA 
probes in common across the platforms for the 2-color data. Note that the 
overall number of miRNAs in common (54) would be the overlap of the 
intersects of these two Venn diagrams. Please also note that the present 
calls for one color analysis will be different from 2-color because the data 
processing is slightly different for the 2 approaches (i.e., there are twice as 
many data points in the two color analysis [dye swap], and the data pro-
cessing involved in the 1 versus 2 color introduces additional variation asso-
ciated with present or absent calls).
Additional file 2 Venn diagram depicting the number of miRNAs in 
common (from Present miRNAs only; 1-color data). A Venn diagram is 
shown for the overlap of miRNA probes in common across the platforms for 
the 1-colour analysis. Note that the overall number of miRNAs in common 
(54) would be the overlap of the intersects of these two Venn diagrams. 
Please also note that the present calls for one color analysis, will be different 
from 2-color because the data processing is slightly different for the 2 
approaches (i.e., there are twice as many data points in the two color analy-
sis [dye swap], and the data processing involved in the 1 versus 2 color 
introduces additional variation associated with present or absent calls).
Additional file 3 Individual Spearman rank correlations. Summary of 
all the individual Spearman rank correlations conducted. R1.1 = Reference 
1, replicate 1. R2.1 = Reference 2, replicate 1. R1.2 = Reference 1, replicate 2. 
R2.1 = Reference 2, replicate 1.
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Additional file 4 Scatterplots for all pair-wise comparisons. Scatter-
plots for all pair-wise comparisons of the log2 ratio of Pool A to Pool B are 
presented for each platform. Present miRNAs are in red, while miRNAs that 
were called 'absent' (i.e., not a high enough signal) are depicted in blue. The 
correlation coefficients (R2), slopes and intercepts are shown in the top left 
corner of the figure for the 'Present' miRNAs, and bottom right corner for 
the 'Absent' miRNAs.
Additional file 5 Correlation of platforms with Taqman RT-PCR. A per-
mutation test was used to test the correlation of platforms with Taqman RT-
PCR (i.e., compare accuracy between platforms). The p-value for testing dif-
ferences between the correlation coefficients was calculated using permu-
tation analysis. Here, 5000 permutations were used to generate the null 
distribution of the test statistic.
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